LIR Life Sciences Corp.
BBCMF
$0.07
-$0.18-73.76%
OTC PK
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 882.41% | 49.68% | |||
| Depreciation & Amortization | 0.00% | 25.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 881.33% | 38.76% | |||
| Operating Income | -881.33% | -38.76% | |||
| Income Before Tax | -1,029.82% | -38.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,029.82% | -38.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,029.82% | -38.43% | |||
| EBIT | -881.33% | -38.76% | |||
| EBITDA | -887.68% | -38.87% | |||
| EPS Basic | -689.04% | -35.19% | |||
| Normalized Basic EPS | -700.00% | -35.29% | |||
| EPS Diluted | -689.04% | -35.19% | |||
| Normalized Diluted EPS | -700.00% | -35.29% | |||
| Average Basic Shares Outstanding | 42.75% | 2.08% | |||
| Average Diluted Shares Outstanding | 42.75% | 2.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||